A covalent peptide-based lysosome-targeting protein degradation platform for cancer immunotherapy
Abstract The lysosome-targeting chimera (LYTAC) strategy provided a very powerful tool for the degradation of membrane proteins. However, the synthesis of LYTACs, antibody-small molecule conjugates, is challenging. The ability of antibody-based LYTACs to penetrate solid tumor is limited as well, esp...
Saved in:
Main Authors: | Youmei Xiao, Zhuoying He, Wanqiong Li, Danhong Chen, Xiaoshuang Niu, Xin Yang, Wenxuan Zeng, Mengfan Wang, Yuzhen Qian, Ye Su, Feiyu Luo, Guanyu Chen, Juan Liu, Xinghua Sui, Xiuman Zhou, Yanfeng Gao |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2025-02-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-025-56648-6 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Bicyclic peptide-enhanced covalent inhibitor of SARS-CoV-2 3CL protease
by: Qian Wang, et al.
Published: (2024-10-01) -
Improving ferroptosis-mediated immunotherapy for colorectal cancer through lysosome-targeted photodynamic therapy
by: Zhian Chen, et al.
Published: (2025-04-01) -
Molecular aspects of cell-penetrating peptides: key amino acids, membrane partners, and non-covalent interactions
by: Walrant, Astrid, et al.
Published: (2025-01-01) -
Resetting the Hsc70-mediated lysosomal degradation of PD-L1 via a supramolecular meso peptide for the restoration of acquired anti-tumor T cell immunity
by: Yujia Zhao, et al.
Published: (2025-02-01) -
Non-covalent interactions in supported asymmetric catalysis: a brief account
by: Ibos, Léa, et al.
Published: (2024-02-01)